Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Novo Nordisk (CPSE:NOVO B) has signed a clinical supply agreement with Veru Inc. to provide Wegovy for a Phase 2b obesity trial in older adults.
The PLATEAU study will test Wegovy alongside Veru’s enobosarm, a selective androgen receptor modulator, in combination therapy.
Novo Nordisk retains no development rights to enobosarm but has secured a right of first negotiation for potential future collaborations with Veru.
For investors tracking CPSE:NOVO B, this agreement comes as the share price stands at DKK283.85, with the stock down 14.1% year to date and down 37.7% over the past year. The company is already a central player in obesity treatments, and this move adds a fresh clinical angle focused on older adults without requiring Novo Nordisk to fund or control development of enobosarm itself.
The deal also gives Novo Nordisk early visibility into combination therapy data that could inform future obesity treatment approaches, while keeping its capital commitments relatively contained. If the PLATEAU trial produces clinically meaningful results, the right of first negotiation positions Novo Nordisk to discuss expanded collaboration with Veru without being locked in under current terms.
Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.
CPSE:NOVO B Earnings & Revenue Growth as at Jun 2026
We’ve flagged 3 risks for Novo Nordisk. See which could impact your investment.
This clinical supply deal is a small but useful piece of optionality for Novo Nordisk. Wegovy is already established as the GLP 1 backbone, and Veru’s PLATEAU trial effectively stress tests how an added muscle preserving agent such as enobosarm might work for older adults who are already on Wegovy for weight loss. Novo Nordisk supplies drug at no cost, gains access to detailed study design, safety updates, and efficacy readouts, but does not carry trial or development risk for enobosarm. The right of first negotiation is important, as it secures a front row seat if combination data look compelling enough for broader development, without committing to license fees or milestones today. For you as an investor, this sits alongside other efforts to widen Wegovy’s use case, such as higher dose formulations and oral pills, and shows the company testing how combination approaches could keep its GLP 1 franchise relevant as Eli Lilly, Viking Therapeutics and smaller biotech players work on their own multi agent obesity regimens.
How This Fits Into The Novo Nordisk Narrative
The PLATEAU collaboration lines up with the existing narrative that product expansion and new treatment formats are important drivers for long term GLP 1 adoption, by probing whether Wegovy can anchor combination therapies in older patients.
At the same time, relying on an external partner for this combination work highlights that execution and outcomes are not fully in Novo Nordisk’s control, which could challenge expectations that it will always lead clinically against Eli Lilly and others.
The specific focus on sarcopenia and muscle function in older adults using a selective androgen receptor modulator is not explicitly covered in most high level obesity narratives, so any success here could add a new dimension that current storylines do not fully reflect.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novo Nordisk to help decide what it’s worth to you.
The Risks and Rewards Investors Should Consider
⚠️ If PLATEAU results are weak, it could reinforce concerns that combination regimens around Wegovy are harder to execute than expected, especially as Eli Lilly and other competitors push their own next generation obesity drugs.
⚠️ Supplying Wegovy at no charge ties product and brand to a partner controlled study, so any safety signal or regulatory scrutiny around combination use could add another layer of risk to a franchise that analysts already flag as central to earnings quality.
🎁 The agreement lets Novo Nordisk test a combination concept in an older population without committing capital to enobosarm development, which can be attractive if you are focusing on risk adjusted pipeline options.
🎁 The right of first negotiation gives Novo Nordisk a preferential position if enobosarm data support a differentiated obesity offering, potentially broadening its GLP 1 portfolio at a time when competition from Eli Lilly and future entrants is intensifying.
What To Watch Going Forward
From here, keep an eye on PLATEAU readouts such as weight loss, muscle mass, function measures and safety in older adults on Wegovy, as these will shape whether combination obesity regimens are worth pursuing. Watch for any follow up agreements between Novo Nordisk and Veru that move beyond clinical supply into co development or licensing, which would signal that Novo Nordisk sees commercial potential in this approach. It is also worth tracking how competitors such as Eli Lilly and Viking Therapeutics frame their own combination or next generation obesity programs, since relative differentiation could influence how much value investors ascribe to partnerships like this.
To stay up to date on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to follow the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com